Trials / Conditions / Excessive Daytime Sleepiness

Excessive Daytime Sleepiness

30 registered clinical trials studyying Excessive Daytime Sleepiness — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Validating a Novel Driving Simulation-based MWT Against the Standard MWT in an OSA-cohort Challenged by CPAP-w NCT06872593	Stefan Lakämper	N/A
Recruiting	A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age NCT07082829	Centessa Pharmaceuticals (UK) Limited	Phase 1
Recruiting	SLEEPINESS - a Search for a Biomarker of Excessive Daytime Sleepiness in Severe Obstructive Sleep Apnoea - An NCT06711159	Zealand University Hospital	—
Completed	Characterization of Children with Complaints of Excessive Daytime Sleepiness NCT06898008	Hospices Civils de Lyon	—
Recruiting	Impact of Bright Light Therapy on Prader-Willi Syndrome NCT05939453	Maimonides Medical Center	N/A
Completed	A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the NCT06103825	Ignis Therapeutics (Suzhou) Limited	Phase 3
Completed	Alternative Epworth Sleepiness Scale ESS-ALT in French NCT05822128	Assistance Publique - Hôpitaux de Paris	—
Completed	A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients With Idiopathic Hypersomni NCT05458128	Harmony Biosciences Management, Inc.	Phase 3
Completed	A Clinical Study to Evaluate the Efficacy and Safety of Pitolisant in the Treatment of EDS in Patients With OS NCT05223166	Citrine Medicine Limited	Phase 3
Completed	A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE NCT05113745	Axsome Therapeutics, Inc.	Phase 3
Completed	A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy NCT05059223	Axsome Therapeutics, Inc.	Phase 3
Completed	Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy NCT04923594	NLS Pharmaceutics	Phase 2
Completed	Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients NCT04886518	Harmony Biosciences Management, Inc.	Phase 2
Completed	Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study NCT04789174	Axsome Therapeutics, Inc.	Phase 4
Completed	BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness NCT03194217	BenevolentAI Bio	Phase 2
Completed	Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy NCT02720744	Avadel	Phase 3
Completed	Pitolisant (BF2.649) in the Treatment of EDS in Patients With OSA NCT02739568	Bioprojet	Phase 3
Completed	Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP) NCT01800045	Bioprojet	Phase 3
Completed	BF2.649 in Patients With OSA, Still Complaining of EDS and Refusing to be Treated by CPAP. NCT01072968	Bioprojet	Phase 3
Completed	BF2.649 in Patients With OSA and Treated by CPAP But Still Complaining of EDS NCT01071876	Bioprojet	Phase 3
Completed	Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA) NCT01620554	Bioprojet	Phase 2
Completed	A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy NCT01006122	Pfizer	Phase 2
Completed	Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy NCT01067235	Bioprojet	Phase 3
Completed	Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy NCT01067222	Bioprojet	Phase 3
Terminated	Treatment of Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea Syndrom NCT00620659	Merck Sharp & Dohme LLC	Phase 2
Completed	Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Diseas NCT00642928	Bioprojet	Phase 2
Completed	Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With N NCT00228566	Cephalon	Phase 3
Completed	Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepine NCT00228553	Cephalon	Phase 3
Completed	Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder NCT00385437	University Health Network, Toronto	Phase 2
Withdrawn	Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoe NCT02978651	Bioprojet	Phase 3